Tonix Pharmaceuticals Holding Corp

Tonix insiders are buying options—signaling confidence in new migraine and fibromyalgia drugs—yet investors should watch upcoming trial results for true upside.

Tonix insiders buying 15,000 shares at $14.89 signals CEO optimism ahead of ACR data, potentially boosting the stock as investors watch for future upside.

Tonix insiders buying zero‑cost options shows confidence in future gains; learn how this move signals upside and what it means for investors.